Medtronic's Sphere-360 Catheter Achieves CE Mark and U.S. Clinical Milestone: A One-Stop Revolution in Atrial Fibrillation Ablation

1.1 Major Approval: A Catheter Initiates a New Paradigm for Atrial Fibrillation Ablation

In January 2026, global medical technology giant Medtronic announced that its Affera Sphere-360 catheter had officially received CE mark approval. This innovative device, which integrates mapping and single-shot pulsed field ablation (PFA) functions, is specifically designed for the treatment of paroxysmal atrial fibrillation, breaking the traditional paradigm of atrial fibrillation ablation therapy.

For a long time, atrial fibrillation, as one of the most common arrhythmias, has seriously threatened the health of more than 33 million patients worldwide. Traditional ablation catheters have many operational inconveniences, requiring doctors to repeatedly rotate the catheter to ensure the ablation effect. This process is not only time-consuming and laborious but also demands extremely high technical skills from the doctors. Moreover, when facing the complex and varied cardiac anatomical structures of different patients, traditional catheters have poor adaptability, making it difficult to achieve precise and efficient treatment.

The emergence of the Medtronic Sphere-360 catheter fills these gaps. With its unique lattice design, it can flexibly deform to adapt to various pulmonary vein anatomical structures, like a highly skilled dancer moving freely through the complex cardiac environment to precisely locate lesions. More impressively, this catheter only requires a single release of pulsed field energy to complete pulmonary vein isolation, truly achieving "instant placement and instant ablation," greatly improving surgical efficiency and allowing patients to be relieved of pain in a shorter time. This marks the entry of atrial fibrillation interventional treatment into a new phase of "precise, efficient, and one-stop completion."

1.2 Dual-track Parallel: European Launch + U.S. Clinical Trials Advancing Simultaneously

At the same time as receiving approval in Europe, Medtronic has completed early patient enrollment in the U.S. multicenter study for the Horizon 360 Investigational Device Exemption (IDE) pivotal trial of the Sphere-360 catheter. This single-arm study focuses on the safety and efficacy of the product in Chinese patients, paving the way for subsequent FDA approval.

This dual strategy of "certification" and "research" highlights Medtronic's leading ambition in the pulsed field ablation (PFA) arena. The initial breakthrough in the European market has enabled the rapid clinical application of the Sphere-360 catheter, benefiting European patients with atrial fibrillation; meanwhile, the steady progress of the U.S. IDE trial represents a crucial step in Medtronic’s strategic planning for the world’s largest healthcare market. Once approved by the FDA, the Sphere-360 catheter is set to spark a new revolution in atrial fibrillation treatment across the U.S. and globally, paving the way for PFA technology to reach an even broader stage.

2.1 Unique Lattice Design: Adapts to Diverse Anatomical Structures, Eliminates Repeated Rotational Operations

In the field of atrial fibrillation ablation, the adaptability between catheters and cardiac anatomical structures has always been a key factor affecting surgical outcomes. Although traditional circular catheters are widely used, their single size often proves inadequate when faced with the highly variable pulmonary vein anatomical morphologies of different patients. Physicians frequently need to spend significant time repeatedly rotating the catheter to achieve optimal contact, which not only prolongs the procedure and increases operational difficulty but may also lead to suboptimal ablation effects due to unstable contact between the catheter and tissue.

The advent of the Sphere - 360 catheter has completely broken this deadlock. Its unique lattice design is exquisite, allowing the catheter to flexibly adjust according to the specific shape of the patient's pulmonary veins, perfectly fitting various complex anatomical structures. Whether it is abnormally dilated, twisted, or has variant branches, the Sphere - 360 catheter can easily handle it, accurately locate the lesion, and lay a solid foundation for ablation therapy.

Paired with an 8.5 French sheath, the Sphere-360 catheter achieves the perfect combination of minimally invasive and high efficiency. The thin-diameter sheath reduces vascular injury and lowers the risk of puncture-related complications. Meanwhile, the catheter can stably adhere to the pulmonary veins without frequent rotation during the procedure, greatly simplifying the surgical operation process. This innovative design did not come out of nowhere but is the crystallization of Medtronic's in-depth research into the needs of clinicians, precisely addressing pain points, bringing unprecedented convenience and efficiency to atrial fibrillation ablation procedures.

2.2 One-stop Integration: Seamless Connection of Mapping + Ablation, Compatible with Established Systems

Atrial Fibrillation Ablation is a "battlefield" where every second counts. How to precisely locate the lesion and perform ablation in the shortest possible time is the goal pursued by every doctor. The Sphere-360 catheter, as an "all-rounder," provides a satisfying answer. It integrates seamlessly with Medtronic's Affera Mapping and Ablation System, which received FDA approval in October 2024, combining the functions of "scouting" and "special operations" into one, achieving seamless integration of mapping and ablation capabilities.

Not only that, but the Sphere-360 catheter supports operation modes with minimal to zero fluoroscopy, which is undoubtedly a double blessing for both doctors and patients. In traditional ablation procedures, prolonged fluoroscopy exposes doctors to radiation risks while also increasing the radiation dose for patients. However, the Sphere-360 catheter, with its advanced electromagnetic navigation technology, can clearly display the catheter's position and cardiac anatomy with almost no reliance on fluoroscopy, allowing the surgery to be performed in a safer and more precise environment—truly embodying the principle of "technology serving people."

2.3 Dual-Energy Technology: Safe and Efficient Ablation Energy Delivery

As the latest achievement in Medtronic's Affera series, the Sphere-360 catheter exhibits outstanding performance in energy delivery. Leveraging the large surface area of lattice electrodes, it delivers PFA energy at a lower current density, akin to a gentle yet precise "assassin," silently performing selective ablation of myocardial cells. This unique energy delivery method not only efficiently destroys abnormal myocardial tissue responsible for atrial fibrillation but also skillfully avoids critical surrounding structures such as the esophagus and phrenic nerve, significantly reducing the risk of surgical complications and ensuring patient safety.

Compared with traditional radiofrequency ablation, the advantage of the Sphere - 360 catheter in achieving pulmonary vein isolation with a single ablation is evident. Traditional radiofrequency ablation often requires multiple repeated ablations, consuming a significant amount of time, and the durability of the ablation effect needs improvement. However, the Sphere - 360 catheter, with its powerful PFA energy, achieves success in one attempt, greatly reducing operation time and alleviating patient discomfort. Clinical research data shows that patients treated with the Sphere - 360 catheter have higher lesion durability and significantly lower atrial fibrillation recurrence rates, offering more lasting and stable treatment outcomes, and opening a "fast track" for atrial fibrillation ablation therapy.

3.1 European Clinical Data: 81.8% No Recurrence of Arrhythmia, Maximum Safety

Clinical data is the "gold standard" for testing the efficacy and safety of medical devices. The Medtronic Sphere-360 catheter delivered impressive results in a European multicenter prospective clinical study. The study included 85 patients with paroxysmal atrial fibrillation, and follow-up results at one year post-operation showed that 81.8% of the patients had no recurrence of arrhythmia. In the subgroup receiving optimized and latest pulse configuration treatment, this proportion soared to 100%.

Not only that, but the average ablation duration was just 10 minutes, truly a "lightning-fast" procedure. This means significantly reduced time for patients on the operating table, not only minimizing surgical risks but also enabling faster recovery. More remarkably, throughout the entire study, there were no reports of severe adverse events such as esophageal injury, pulmonary vein stenosis, or cardiac tamponade, with all safety indicators showing exceptional results. This data not only validates the high efficiency of the Sphere-360 catheter in treating paroxysmal atrial fibrillation but also highlights its outstanding safety, providing both patients and doctors with genuine "peace of mind."

3.2 Doctor's Authoritative Endorsement: Balancing Usability and Efficacy, Reshaping Clinical Treatment Experience

Good medical devices not only need to have solid data but also gain recognition from clinicians. Dr. Tobias Reichlin, Director of Electrophysiology at Bern University Hospital in Switzerland, did not hesitate to praise the Sphere-360 catheter: "This catheter achieves a perfect balance between ease of use and consistent efficacy. Its unique design allows it to conform to the pulmonary veins in an unprecedented way, creating consistent, effective, and long-lasting lesions for atrial fibrillation patients without the need to rotate the catheter." In his view, this design, which eliminates the need for repeated catheter rotation, greatly reduces the complexity of the surgical procedure, allowing doctors to focus more on the surgery itself and improve the success rate of the operation.

Dr. Vivek Reddy, Director of the Cardiac Arrhythmia Center at Mount Sinai Hospital in the United States, also favors the Sphere-360 catheter. He noted: "The lattice-tip design of Sphere-360 breaks through the limitation of traditional catheters requiring repeated rotational positioning. Its 'place-and-ablate' feature significantly reduces procedural complexity, making it especially suitable for beginners and patients with complex anatomical structures." For experienced doctors, the Sphere-360 catheter helps them complete surgeries more efficiently; for those new to the field of electrophysiology, this catheter provides a more user-friendly and easy-to-operate platform, helping them quickly gain experience and improve surgical skills. These high praises from authoritative experts undoubtedly strongly endorse the clinical value of the Sphere-360 catheter, making many doctors highly anticipate this product.

4.1 Europe Benefits First: Filling the Unmet Needs in Atrial Fibrillation Treatment

Successful Approval of CE Certification Allows Medtronic's Sphere-360 Catheter to Take the Lead in the European Market, Bringing New Hope to Local Atrial Fibrillation Patients. As a forefront for global medical technology application, Europe has a high acceptance of innovative medical devices. Statistics show that the number of atrial fibrillation patients in Europe is substantial and continues to rise annually with the aggravation of an aging society. Traditional atrial fibrillation treatment methods are increasingly revealing limitations such as limited efficacy and higher surgical risks when addressing such a large patient population, making the demand for safer and more efficient treatment solutions increasingly urgent.

Sphere - 360 Catheter Emerges as a Perfect Solution to Meet This Unmet Need. Its unique design and advanced technology significantly reduce operation time from several hours in traditional ablation procedures to just tens of minutes, greatly alleviating patient suffering and surgical risks. Moreover, the catheter can provide precise treatment tailored to individual patient differences, effectively improving the success rate and durability of treatments while reducing the recurrence rate of atrial fibrillation. This not only offers patients a better treatment experience but also alleviates the long-term medical burden on European healthcare systems. It is expected to become the new gold standard for atrial fibrillation treatment in Europe, leading the industry trend.

4.2 Acceleration of Clinical Trials in the U.S.: Aiming for FDA Approval to Capture a $100 Billion Market

Although the Sphere-360 catheter has not yet received FDA approval, the smooth progress of the Horizon 360 IDE trial has raised expectations for its entry into the U.S. market. As the world's largest medical device market, the United States boasts a large patient population and a well-established healthcare system, with a medical device market size reaching hundreds of billions of dollars. For Medtronic, once the Sphere-360 catheter receives FDA approval, it will quickly access the U.S. and even the global market, further solidifying its leading position in the PFA field.

The U.S. market has extremely stringent approval processes for medical devices, and FDA approval not only signifies recognition of a product's safety and efficacy but also serves as the "passport" for entering the mainstream market. Medtronic is well aware of this, which is why in the Horizon 360 IDE trial, they meticulously designed the study protocol and rigorously controlled the trial quality to ensure that the Sphere-360 catheter could withstand the FDA's rigorous scrutiny. Once approved, the Sphere-360 catheter, with its superior performance, will compete head-on with rivals such as Boston Scientific and Johnson & Johnson for a share of the electrophysiology market. It is expected to carve out a significant position in this billion-dollar market, driving Medtronic's business growth in the global medical market.

4.3 Winning through Technology Integration: Releasing Strategic Benefits after Acquiring Affera

In 2022, Medtronic's acquisition of Affera for $1 billion did not attract much attention at the time, but in hindsight, it has become a key step in Medtronic's rise in the electrophysiology field. After acquiring Affera, Medtronic successfully filled the gap in its mapping system capabilities, achieving complementary technical advantages.

The success of the Sphere-360 catheter is a testament to Medtronic's technical integration following its acquisition of Affera. Leveraging Affera's lattice catheter technology, Medtronic was able to develop the Sphere-360 catheter with a unique lattice design. Combined with Medtronic’s robust energy platform, this enabled the seamless integration of mapping and ablation functions. This integration not only marked a breakthrough for Medtronic in PFA technology but also made it the first company globally to possess two FDA-approved PFA systems, successfully reshaping the competitive landscape of the electrophysiology market.

Today, Medtronic has formed a strong product matrix in the PFA field with the Sphere-360 catheter and Sphere-9 catheter, which can meet the treatment needs of different patients. The strategic benefits brought by this technological integration will continue to drive Medtronic's development in the electrophysiology market, enabling it to occupy a more advantageous position in future competition and lead the industry in technological innovation and development direction.

Currently, the global PFA track is becoming increasingly competitive, with giants such as Boston Scientific and Johnson & Johnson making strategic moves. Each product has its own focus in terms of design, functionality, and approval progress, as detailed in the comparison below:

5.1 For Patients: A New, Safer, and More Efficient Treatment Option for Atrial Fibrillation

The birth of the Medtronic Sphere-360 catheter has brought an unprecedented treatment experience to patients with atrial fibrillation. For those who have long suffered from atrial fibrillation, issues such as large trauma, slow recovery, and high recurrence rates associated with traditional ablation surgeries have been like heavy shackles, limiting their quality of life. This "one-stop" catheter, with its unique design and advanced technology, has given patients a glimpse of hope.

Minimally Invasive and Rapid Recovery Are Key Highlights of the Sphere-360 Catheter. The application of its 8.5 French sheath significantly reduces vascular trauma during surgery, lowering the risk of postoperative complications such as infection and bleeding. Patients experience a substantially shortened recovery time, allowing them to return to normal life more quickly while reducing physical and mental burdens. Moreover, the catheter’s precise ablation capability markedly enhances the durability of treatment outcomes. Clinical data shows that in patients treated with the Sphere-360 catheter, the recurrence rate of arrhythmia was as low as 18.2% one year post-surgery (with a recurrence rate of 0% in the subgroup treated with optimized and latest pulse configuration). This means patients can maintain a healthy state for a longer period, avoiding the distress of frequent medical visits and repeat surgeries.

For some complex anatomical cases where traditional ablation is less effective, the Sphere-360 catheter demonstrates unique advantages. Its deformable lattice design can perfectly conform to various complex pulmonary vein anatomical structures, achieving precise ablation and effectively improving treatment success rates. For instance, in complex situations such as abnormal pulmonary vein openings or excessive branching, traditional catheters often struggle to achieve ideal ablation results, whereas the Sphere-360 catheter can easily address these challenges, offering the possibility of a cure for these patients.

5.2 For the industry: Doctor demand-oriented R&D, leading the direction of technological innovation

From the perspective of R&D philosophy, the Sphere-360 catheter is a prime example of physician-demand-driven development. Medtronic delves into clinical frontlines, extensively gathering pain points and needs from electrophysiologists during actual procedures, using these insights as the foundation for product design and innovation. This approach—starting from clinical practice to reverse-drive product development—sets a benchmark for the medical device industry, making products more aligned with real clinical needs and truly achieving "patient-centered care, guided by physicians."

At the technological innovation level, the successful approval of the Sphere-360 catheter has undoubtedly injected strong momentum into the development of PFA technology. Its emergence has driven the entire electrophysiology treatment field towards more precise, efficient, and safer directions. In the future, with continuous technological iteration, PFA devices are expected to achieve breakthroughs in more arrhythmia fields, such as ventricular tachycardia and atrial tachycardia. Medtronic has already initiated research utilizing the radiofrequency capabilities of the Sphere-9 catheter to develop an integrated solution for mapping and ablation of ventricular tachycardia, which has been granted "Breakthrough Device Designation" by the FDA. This indicates that PFA technology is set to usher in a new era of electrophysiology treatment, bringing good news to more patients with arrhythmias.

5.3 Market Prospects: The Race in the Billion-Dollar PFA Track, with Innovators Taking the Lead

According to predictions by authoritative industry institutions, the global PFA equipment market is in a golden period of rapid growth. It is expected that by 2028, the market size will exceed 3.2 billion US dollars, with an annual growth rate of over 25%. This rapid development trend is driven by the significant advantages of PFA technology compared to traditional ablation technologies, as well as the continuous increase in the number of atrial fibrillation patients worldwide.

In this fierce market competition, Medtronic, with the technical advantages and global layout of the Sphere-360 catheter, is expected to capture more than 40% of the market share and continue to lead the PFA field. Its early approval in Europe and the steady progress of the IDE trial in the United States have laid a solid foundation for the global promotion of the product. Moreover, Medtronic's acquisition of Affera has enabled technological integration and complementary advantages, building a robust product portfolio that can better meet the treatment needs of different patients, further strengthening its market position.

Of course, market competition has never been dominated by a single player. Medical giants such as Boston Scientific and Johnson & Johnson are also actively positioning themselves in the PFA field, launching their own innovative products. For example, Boston Scientific's Farapulse pulsed field ablation system has been used globally to treat over 40,000 patients. Its unique catheter design and energy transmission method have also secured its place in the market. However, Medtronic's Sphere-360 catheter stands out among many competitors with its distinctive lattice design, one-stop integrated functionality, and excellent clinical data, becoming a benchmark product in the industry.

Medtronic Affera Sphere-360 Catheter Receives CE Mark Approval, Marking a Milestone in Atrial Fibrillation Treatment. It not only offers patients a safer and more efficient treatment option but also sets a direction for innovation and development in the medical device industry. With continuous technological advancements and market expansion, PFA technology is bound to shine even brighter in the field of arrhythmia treatment. Let us wait and see.

This Issue's Planning: Shen Li

Editor-in-Chief: Chen Baolin

Author of this article: Yun Ye Xuan

Post-production: Zhang Lirong